BGP - 15,>= 98%( HPLC )

Code: b4813-25mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.

Biochem/physiol Actions

BGP-15 is PAR...


en savoir plus

Votre prix
£503.00 25MG

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.

Biochem/physiol Actions

BGP-15 is PARP inhibitor, HSP72 activator.

General description

BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF).

Packaging

5, 25 mg in glass bottle

assay≥98% (HPLC)
formsolid
InChI keyISGGVCWFTPTHIX-UHFFFAOYSA-N
InChI1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
Quality Level100
SMILES stringCl.Cl.NC(=N/OCC(O)CN1CCCCC1)c2cccnc2
solubilitydeionized water: 28 mg/mL
storage temp.−20°C
Code
Description
Unité de vente
Prix annoncé
Qté
B4813-5MG
Unité:5MG
Prix annoncé: £148.00
Source:Prix annoncé
Cas Number0951628-79-8
Hazard Class6.1
Un Number2811
Pack Group3
Ce produit répond aux critères suivants: